Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Simulations Plus to Present at Oppenheimer Annual Healthcare Conference


Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that management will be presenting at Oppenheimer’s 32nd Annual Healthcare Conference taking place virtually from March 15-16, 2022.

Shawn O’Connor, chief executive officer, will present on Tuesday, March 15, 2022, at 4:00 p.m. ET. In addition, Mr. O’Connor will be available to host one-on-one meetings throughout the day. To listen to the live event or request a one-on-one meeting, please contact your Oppenheimer representative. The Company’s slide presentation will be available on the Investors page of the Simulations Plus website following the presentation.

For more information about the Oppenheimer Annual Healthcare Conference, or to register to attend, please visit the conference website or contact Brian Siegel from Hayden IR at [email protected].

About Simulations Plus

Serving clients worldwide for 25 years, Simulations Plus is a leading provider in the biosimulation market providing software and consulting services supporting drug discovery, development, research, and regulatory submissions. We offer solutions that bridge machine learning, physiologically based pharmacokinetics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. Our technology is licensed and applied by major pharmaceutical, biotechnology, and regulatory agencies worldwide. For more information, visit our website at www.simulations-plus.com. Follow us on Twitter | LinkedIn.

Environmental, Social, and Governance (ESG)

We focus our Environmental, Social, and Governance (ESG) efforts where we can have the most positive impact. To learn more about our latest initiatives and priorities, please visit our website to read our ESG Report.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220308005001/en/

Simulations Plus Aktie

34,00 €
4,29 %
Die Simulations Plus Aktie verzeichnet heute einen großen Anstieg um 4,29 %.
Die Simulations Plus Aktie genießt klare Unterstützung: Mehrere Buy-Einschätzungen, keine Sell-Einschätzungen.
Eine erhebliche Steigerung um mehr als 20% ist für Simulations Plus mit einem Kursziel von 51 € im Vergleich zum aktuellen Kurs von 34.0 € zu erwarten.
Like: 0
Teilen
Business Wire, a Berkshire Hathaway company, is the global leader in press release distribution and regulatory disclosure. Investor relations, public relations, public policy and marketing professionals rely on Business Wire for secure and accurate distribution of market-moving news and multimedia.

Rechtlicher Hinweis

Kommentare